Clinical Trial Search

Primary: Overall Objective Response — 0; 0; 2; 0 participants

Primary: Overall Response Rate (ORR) — 12; 0; 0; 0 participants

Primary: Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo — -1.8; -2.0; -0.6 wheal…

Primary: Radiographic Response Assessed by Macdonald Criteria Every 2 Months — 3; 2; 4; 3 participants

Primary: Number of Participants With Erythroid Response — 5 participants

Primary: To Determine the Effects of Sho-saiko-to on Hepatic Injury in Patients With Chronic Hepatitis C Who Are Intolerant or Have a Specific Contraindication to…

Primary: Change in Cognitive Performance — 0.8; 0.7; 1.2; 0.4 units on a scale — p=<0.0125

Primary: Objective Response Rate in Patients With Cancers Other Than Melanoma — 0 percentage of participants

Primary: Cmax of Vortioxetine — 4.3; 7.8; 15; 16 ng/mL

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 95.5; 90.9; 95.2; 95.0 percentage of participants

Primary: Number of Participants With Adverse Events (AEs) — 12; 13; 14; 12 participants

Primary: Percentage of Patients Experiencing Hemorrhagic Cystitis Post Transplant — 30 percentage of patients

Primary: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations Due to AEs — 92; 52; 10; 33 participants

Primary: Percent Marijuana-negative Urine Drug Screens (UDS) — 5.5; 3.6 percentage of UDS

Primary: Median Progression Free Survival (PFS) — 3; 1.2 months — p=0.0001